Endoscopy 2006; 38(9): 867-872
DOI: 10.1055/s-2006-944726
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Autofluorescence endoscopy in surveillance of Barrett’s esophagus: a multicenter randomized trial on diagnostic efficacy

J.  Borovicka1 , J.  Fischer2 , J.  Neuweiler3 , P.  Netzer4 , J.  Gschossmann4 , T.  Ehmann5 , P.  Bauerfeind6 , G.  Dorta5 , U.  Zürcher1 , J.  Binek1 , C.  Meyenberger1
  • 1Division of Gastroenterology/Hepatology, Dept. of Internal Medicine, Cantonal Hospital, St. Gallen, Switzerland
  • 2Dept. of Public Health, Social and Preventive Medicine, Mannheim Medical School, Heidelberg University, Germany
  • 3Institute of Pathology, St. Gallen, Switzerland
  • 4Division of Gastroenterology, University Hospital, Berne, Switzerland
  • 5Division of Gastroenterology, University Hospital, Lausanne, Switzerland
  • 6Division of Gastroenterology, University Hospital, Zurich, Switzerland
Further Information

Publication History

Submitted 19 January 2006

Accepted after revision 6 June 2006

Publication Date:
18 September 2006 (online)

Background and study aims: The reference surveillance method in patients with Barrett’s esophagus is careful endoscopic observation, with targeted as well as random four-quadrant biopsies. Autofluorescence endoscopy (AFE) may make it easier to locate neoplasia. The aim of this study was to elucidate the diagnostic accuracy of surveillance with AFE-guided plus four-quadrant biopsies in comparison with the conventional approach.
Patients and methods: A total of 187 of 200 consecutive Barrett’s esophagus patients who were initially enrolled (73 % male, mean age 67 years, mean Barrett’s segment length 4.6 cm), who underwent endoscopy for Barrett’s esophagus in four study centers, were randomly assigned to undergo either AFE-targeted biopsy followed by four-quadrant biopsies or conventional endoscopic surveillance, also including four-quadrant biopsies (study phase 1). After exclusion of patients with early cancer or high-grade dysplasia, who underwent endoscopic or surgical treatment, as well as those who declined to participate in phase 2 of the study, 130 patients remained. These patients were examined again with the alternative method after a mean of 10 weeks, using the same methods described. The main study parameter was the detection of early cancer/adenocarcinoma or high-grade dysplasia (HGD), comparing both approaches in study phase 1; the secondary study aim in phase 2 was to assess the additional value of the AFE-guided approach after conventional surveillance, and vice versa. Test accuracy measures were derived from study phase 1.
Results: In study phase 1, the AFE and conventional approaches yielded adenocarcinoma/HGD rates of 12 % and 5.3 %, respectively, on a per-patient basis. With AFE, four previously unrecognized adenocarcinoma/HGD lesions were identified (4.3 % of the patients); with the conventional approach, one new lesion (1.1 %) was identified. Of the 19 adenocarcinoma/HGD lesions detected during AFE endoscopy in study phase 1, eight were visualized, while 11 were only detected using untargeted four-quadrant biopsies (sensitivity 42 %). Of the 766 biopsies classified at histology as being nonneoplastic, 58 appeared suspicious (specificity 92 %, positive predictive value 12 %, negative predictive value 98.5 %). In study phase 2, AFE detected two further lesions in addition to the initial alternative approach in 3.2 % of cases, in comparison with one lesion with conventional endoscopy (1.7 %).
Conclusions: In this referral Barrett’s esophagus population with a higher prevalence of neoplastic lesions, the AFE-guided approach improved the diagnostic yield for neoplasia in comparison with the conventional approach using four-quadrant biopsies. However, AFE alone was not suitable for replacing the standard four-quadrant biopsy protocol.

References

  • 1 Corley D A, Levin T R, Habel L A. et al . Surveillance and survival in Barrett’s adenocarcinomas: a population-based study.  Gastroenterology. 2002;  122 633-640
  • 2 Spechler S J, Goyal R K. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett.  Gastroenterology. 1996;  110 614-621
  • 3 Streitz J M, Ellis F H, Tilden R L. et al . Endoscopic surveillance of Barrett’s esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.  Am J Gastroenterol. 1998;  93 911-915
  • 4 Hurschler D, Borovicka J, Neuweiler J. et al . Increased detection rates for Barrett’s oesophagus without rise in incidence of oesophageal adenocarcinoma - a ten-year survey in Eastern Switzerland.  Swiss Med Wkly. 2003;  133 507-514
  • 5 Drewitz D J, Sampliner R E, Garewal H S. The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years.  Am J Gastroenterol. 1997;  92 212-215
  • 6 Reid B J, Blount P L, Rubin C E. et al . Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort.  Gastroenterology. 1992;  102 1212-1219
  • 7 Weston A P, Badr A S, Hassanein R S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett’s multifocal high-grade dysplasia or adenocarcinoma.  Am J Gastroenterol. 1999;  94 3413-3419
  • 8 Levine D S. Management of dysplasia in the columnar-lined esophagus.  Gastroenterol Clin North Am. 1997;  26 613-634
  • 9 Stepp H, Sroka R, Baumgartner R. Fluorescence endoscopy of gastrointestinal diseases: basic principles, techniques, and clinical experience.  Endoscopy. 1998;  30 379-386
  • 10 Arens C, Dreyer T, Glanz H. et al . Indirect autofluorescence laryngoscopy in the diagnosis of laryngeal cancer and its precursor lesions.  Eur Arch Otorhinolaryngol. 2004;  261 71-76
  • 11 Stepinac T, Felley C, Jornod P. et al . Endoscopic fluorescence detection of intraepithelial neoplasia in Barrett’s esophagus after oral administration of aminolevulinic acid.  Endoscopy. 2003;  35 663-668
  • 12 Vo-Dinh T, Panjehpour M, Overholt B F. Laser-induced fluorescence for esophageal cancer and dysplasia diagnosis.  Adv Opt Biopsy Opt Mammogr. 1998;  838 116-22
  • 13 Egger K, Werner M, Meining A. et al . Biopsy surveillance is still necessary in patients with Barrett’s oesophagus despite new endoscopic imaging techniques.  Gut. 2003;  52 18-23
  • 14 Niepsuj K, Niepsuj G, Cebula W. et al . Autofluorescence endoscopy for detection of high-grade dysplasia in short-segment Barrett’s esophagus.  Gastrointest Endosc. 2003;  58 715-719
  • 15 Mayinger B, Horner P, Jordan M. et al . Light-induced autofluorescence spectroscopy for the endoscopic detection of esophageal cancer.  Gastrointest Endosc. 2001;  54 195-201
  • 16 Haggitt R C. Barrett’s esophagus, dysplasia, and adenocarcinoma.  Hum Pathol. 1994;  25 982-993
  • 17 Kara M A, Smits M E, Rosmolen W D. et al . A randomized crossover study comparing light-induced fluorescence endoscopy with standard videoendoscopy for the detection of early neoplasia in Barrett’s esophagus.  Gastrointest Endosc. 2005;  61 671-678
  • 18 Kara M A, Peters F P, ten Kate F J. et al . Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett’s esophagus.  Gastrointest Endosc. 2005;  61 679-685
  • 19 Herth F JF, Ernst A, Becker H D. Autofluorescence bronchoscopy: a comparison of two systems (LIFE and D-light).  Respiration. 2003;  70 395-398
  • 20 Buttar N S, Wang K K, Sebo T J. et al . Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma.  Gastroenterology. 2001;  120 1630-1639

J. Borovicka, M. D.

Division of Gastroenterology/Hepatology · Dept. of Internal Medicine · Cantonal Hospital

9007 St. Gallen · Switzerland

Fax: +41-71-494-2862

Email: jan.borovicka@kssg.ch

    >